Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study

PLoS ONE

Volumn 8, Issue 7, 2013, Pages

  Wu, Jianhua ^a   Zhu, Shihua ^b   Yao, Guiqing Lily ^c   Mohammed, Mohammed A ^b   Marshall, Tom ^b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; GENERAL PRACTICE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIMARY PREVENTION; RETROSPECTIVE STUDY; SYSTOLIC BLOOD PRESSURE; UNITED KINGDOM;

ADULT; AGED; CARDIOVASCULAR DISEASES; DRUG PRESCRIPTIONS; FEMALE; GENERAL PRACTICE; GREAT BRITAIN; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PHYSICIAN'S PRACTICE PATTERNS; PRIMARY PREVENTION; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84880813036     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0067611     Document Type: Article

References (68)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (8934):: 1383-9.
2. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, et al. (1998) Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 279 (20):: 1615-22.
3. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, et al. (1995) Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. The New England Journal of Medicine 333 (20):: 1301-7.
4. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, et al. (1996) The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. The New England Journal of Medicine 335 (14):: 1001-9.
5. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, (1998) Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. The Canadian Journal of Cardiology 14 Suppl A: 17A-21A.
6. National Cholesterol Education Program (2002) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (25):: 3143-421.
7. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, et al. (2003) European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. European Heart Journal 24 (17):: 1601-10.
8. Scottish Intercollegiate Guidelines Network SIGN 97 (2007) Risk estimation and the prevention of cardiovascular disease a national clinical guideline Scottish Intercollegiate Guidelines Network Available: http://www.sign.ac.uk/guidelines/fulltext/93-97/index.html. Accessed 2012 May 9.
9. Wood D, Wray R, Poulter N, Williams B, Kirby M, et al. (2005) JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart 91. Suppl 5: v1-52.
10. National Institute for Clinical Excellence (2008) Type 2 diabetes Clinical guidelines CG66 Issued: May Available: http://guidance.nice.org.uk/CG66. Accessed 2012 Apr 24.
11. National Institute for Clinical Excellence. (2008) Clinical Guidelines and Evidence Review for Lipid Modification: cardiovascular risk assessment and the primary and secondary prevention of cardiovascular disease. Clinical Guidelines CG67. Issued May. Available: http://publications.nice.org.uk/lipid-modification-cg67. Accessed 2012 Apr 24.
12. New Zealand Guidelines Group (2003) Assessment and management of cardiovascular risk. NZGG.
13. Krum H, Jelinek MV, Stewart S, Sindone A, Atheton JJ, (2001) Lipid management guidelines. National Heart Foundation of Australia, The Cardiac Society of Australia and New Zealand. The Medical Journal of Australia 194: S57-S85.
14. Anderson KM, Odell PM, Wilson PW, Kannel WB, (1991) Cardiovascular disease risk profiles. American Heart Journal 121 (1 Pt 2):: 293-8.
15. National Institute for Clinical Excellence (2008) CG71 Familial hypercholesterolaemia: NICE guideline. Issued August. Available: http://publications.nice.org.uk/lipid-modification-cg71. Accessed 2012 Apr 24.
16. Page IH, Berrettoni JN, Butkus A, Sones FM Jr, (1970) Prediction of coronary heart disease based on clinical suspicion, age, total cholesterol, and triglyceride. Circulation 42 (4):: 625-45.
17. Blackburn H, (1974) Editorial: Prediction and prognostication in coronary heart disease. New England Journal of Medicine 290 (23):: 1315-6.
18. Keys A, Aravanis C, Blackburn H, Van Buchen FSP, Buzina R, et al. (1972) Probability of middle aged men developing coronary heart disease in five years. Circulation 54: 815-28.
19. Menotti A, Corradini P, Capocaccia R, Farchi G, Mariotti S, et al. (1975) The prediction of coronary heart disease. A mathematical model applied to Italian field studies (author's transl). [Italian] Giornale Italiano di Cardiologia 5 (6):: 843-9.
20. Rosenman RH, Brand RJ, Sholtz RI, Friedman M, (1976) Multivariate prediction of coronary heart disease during 8.5 year follow-up in the Western Collaborative Group Study. American Journal of Cardiology 37 (6):: 903-10.
21. Richard JL, Ducimetiere P, Bonnaud G, Claude JR, Lellouch J, et al. (1977) [Incidence and evaluation of the risk of coronary disease. Prospective study in Paris]. [French] Archives des Maladies du Coeur et des Vaisseaux 70 (5):: 531-40.
22. Kannel WB, McGee D, Gordon T, (1976) A general cardiovascular risk profile: the Framingham study. American Journal of Cardiology 38: 46-51.
23. Brand RJ, Rosenman RH, Sholtz RI, Friedman M, (1976) Multivariate prediction of coronary heart disease in the Western Collaborative Group Study compared to the findings of the Framingham study. Circulation 53 (2):: 348-55.
24. Weinstein MC, Stason WB, (1978) Economic considerations in the management of mild hypertension. Annals of the New York Academy of Science 304: 424-38.
25. Assmann G, (1990) At what levels of total low- or high-density lipoprotein cholesterol should diet/drug therapy be initiated? European guidelines. American Journal of Cardiology 65 (12):: 11F-15F.
26. Shepherd J, Betteridge DJ, Durrington P, Laker M, Lewis B, et al. (1987) Strategies for reducing coronary heart disease and desirable limits for blood lipid concentrations: guidelines of the British Hyperlipidaemia Association. British Medical Journal 295: 1245-6.
27. Anonymous (1990) Guidelines for the detection of high-risk lipoprotein profiles and the treatment of dyslipoproteinemias. Canadian Lipoprotein Conference Ad Hoc Committee on Guidelines for Dyslipoproteinemias. Canadian Medical Association Journal 142 (12):: 1371-82.
28. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (1988) Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Archives of Internal Medicine 148: 36-69.
29. Haq IU, Jackson PR, Yeo WW, Ramsay LE, (1995) Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet 346 (8988):: 1467-71.
30. Frohlich J, Fodor G, McPherson R, Genest J, Langner N, (1998) Rationale for and outline of the recommendations of the Working Group on Hypercholesterolemia and Other Dyslipidemias: interim report. Dyslipidemia Working Group of Health Canada. Canadian Journal of Cardiology 14 Suppl A: 17A-21A.
31. Anonymous (2002) National Cholesterol Education Program (NCEP). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 106 (25):: 3143-421.
32. Wood D, Durrington P, Poulter N, McInnes G, Rees A, et al. (1998) Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 80: Supplement 2.
33. Mohammed MA, el Sayed C, Marshall T, (2012) Patient and Other Factors Influencing the Prescribing of Cardiovascular Prevention Therapy in the General Practice Setting With and Without Nurse Assessment. Medical Decision Making 32 (3):: 498-507 DOI 10.11770272989X12437246. Med Decision Making 0272989X12437246.
34. THIN data. Available: http://www.epic-uk.org/our-data/statistics.html. Accessed 2012 Apr 15.
35. Cegedim Strategic Data. Available: http://csdmruk.cegedim.com/our-data/our-data.shtml. CSD Medical Research 2012. Accessed 2012 Jun 29.
36. Maguire A, Blak BT, Thompson M, (2009) The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiology and Drug Safety 18 (1):: 76-83.
37. Townsend P, Phillimore P, Beattie A (1988) Health and Deprivation: Inequality and the North. Croom Helm Ltd, London.
38. NHS Connecting for Health Read Codes. Available: http://www.connectingforhealth.nhs.uk/systemsandservices/data/uktc/readcodes. Accessed 2013 Feb 18.
39. Marston L, Carpenter JR, Walters KR, Morris RW, Nazareth I, et al. (2010) Issues in multiple imputation of missing data for large general practice clinical databases. Pharmacoepidemiol Drug Saf 19 (6):: 618-26 doi:10.1002/pds.1934.
40. Prescription Cost Analysis, England - 2011 (2012) The NHS Information Centre Available: http://www.ic.nhs.uk/statistics-and-data-collections/primary-care/prescriptions/prescription-cost-analysis-england-2011. Accessed 2012 Apr 25.
41. Williams RR, Hunt SC, Schumacher C, Hegele RA, Leppert MF, et al. (1993) Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics. American Journal of Cardiology 72: 171-6.
42. Goldstein JL, Brown MS (1983) Familial hypercholesterolaemia. In: Stanbury JB, Wyngaarden JB, Fredrickson DS, Goldstein JL, Brown MS, editors. The metabolic basis of inherited disease, 5th edn. New York: McGraw-Hill;672-712.
43. Bryan S, Gill P, Greenfield S, Gutridge K, Marshall T, (2006) Predictors of patients' preferences for treatments to prevent heart disease. Heart 92 (11):: 1651-5.
44. Montgomery AA, Harding J, Fahey T, (2001) Shared decision making in hypertension: the impact of patient preferences on treatment choice. Family Practice 18 (3):: 309-13.
45. Bryan S, Gill P, Greenfield S, Gutridge K, Marshall T, (2006) The myth of agency and patient choice in health care? The case of drug treatments to prevent coronary disease. Social Science and Medicine 63 (10):: 2698-701.
46. Ma J, Sehgal NL, Ayanian JZ, Stafford RS, (2005) National trends in statin use by coronary heart disease risk category. PLoS Medicine 2 (5):: e123.
47. Mantel-Teeuwisse AK, Verschuren WM, Klungel OH, Kromhout D, Lindemans AD, et al. (2003) Undertreatment of hypercholesterolaemia: a population-based study. British Journal of Clinical Pharmacology 55 (4):: 389-97.
48. Selmer R, Sakshaug S, Skurtveit S, Furu K, Tverdal A, (2009) Statin treatment in a cohort of 20 212 men and women in Norway according to cardiovascular risk factors and level of education. British Journal of Clinical Pharmacology 67 (3):: 355-62.
49. Tonstad S, Rosvold EO, Furu K, Skurtveit S, (2004) Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. Journal of Internal Medicine 255 (4):: 494-502.
50. Forde I, Chandola T, Raine R, Marmot MG, Kivimaki M, (2011) Socioeconomic and ethnic differences in use of lipid-lowering drugs after deregulation of simvastatin in the UK: the Whitehall II prospective cohort study. Atherosclerosis 215 (1):: 223-8.
51. Ashworth M, Lloyd D, Smith RS, Wagner A, Rowlands G, (2007) Social deprivation and statin prescribing: a cross-sectional analysis using data from the new UK general practitioner 'Quality and Outcomes Framework'. Journal of Public Health 29 (1):: 40-7.
52. Macklin J, Morrison G, (2011) Survey of general practitioners' attitudes to prescribing statins in different patient groups: a web-based survey. Scottish Medical Journal 56 (1):: 33-5.
53. Stafford L, Harmer N, Dhaliwal S, Jiwa M, (2009) Statin initiation by GPs in WA-a structured vignette study. Australian Family Physician 38 (9):: 739-42.
54. Barham AH, Goff DC Jr, Chen H, Balasubramanyam A, Rosenberger E, et al. (2009) Appropriateness of cholesterol management in primary care by sex and level of cardiovascular risk. Prev Cardiol. Spring 12 (2):: 95-101 doi:10.1111/j.1751-7141.2008.00019.x.
55. Verma A, Visintainer P, Elarabi M, Wartak S, Rothberg MB, (2012) Overtreatment and undertreatment of hyperlipidemia in the outpatient setting. South Med J 105 (7):: 329-33 doi:10.1097/SMJ.0b013e318259bad3.
56. Roumie CL, Elasy TA, Wallston KA, Pratt S, Greevy RA, et al. (2007) Clinical inertia: a common barrier to changing provider prescribing behavior. The Joint Commission Journal on Quality and Patient Safety 33 (5):: 277-85.
57. Hippisley-Cox J, Vinogradova Y (2009) Trends in Consultation Rates in General Practice- 1995/1996-2008/2009: analysis of the QResearch database The Information Centre for Health and Social Care. Available: http://www.ic.nhs.uk. Accessed 2013 Feb 19.
58. Abookire SA, Karson AS, Fiskio J, Bates DW, (2001) Use and monitoring of "statin" lipid-lowering drugs compared with guidelines. Archives of Internal Medicine 161 (1):: 53-8.
59. van Duijn HJ, Belo JN, Blom JW, Velberg ID, Assendelft WJ, (2011) Revised guidelines for cardiovascular risk management- time to stop medication? A practice-based intervention study. British Journal of General Practice 61 (587):: e347-52.
60. Lopez-Carmona D, Bernal-Lopez M, Mancera-Romero J, Jansen-Chaparro S, Portales-Fernandez I, et al. (2012) Compliance with cardiovascular drug prevention measures in a general population: the Multidisciplinary Intervention in Primary Care (IMAP) study. Eur J Prev Cardiol 19 (5):: 1074-81 doi:10.1177/1741826711418166. Epub 2011 Aug 2.
61. Christian AH, Mills T, Simpson SL, Mosca L, (2006) Quality of cardiovascular disease preventive care and physician/practice characteristics. Journal of General Internal Medicine 21 (3):: 231-7.
62. Petursson H, Getz L, Sigurdsson JA, Hetlevik I, (2009) Current European guidelines for management of arterial hypertension: are they adequate for use in primary care? Modelling study based on the Norwegian HUNT 2 population. BMC Family Practice 10: 70.
63. Getz L, Sigurdsson JA, Hetlevik I, (2003) Is opportunistic disease prevention in the consultation ethically justifiable? BMJ 327 (7413):: 498-500.
64. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, et al. (2003) Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. European Heart Journal 24 (11):: 987-1003.
65. Ohlsson H, Merlo J, (2009) Is physician adherence to prescription guidelines a general trait of health care practices or dependent on drug type?-A multilevel logistic regression analysis in South Sweden. Pharmacoepidemiology and Drug Safety 18 (8):: 682-90.
66. McBride P, Schrott HG, Plane MB, Underbakke G, Brown RL, (1998) Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Archives of internal medicine 158 (11):: 1238-44.
67. Gumbs PD, Verschuren WM, Mantel-Teeuwisse AK, de Wit AG, Hofman A, et al. (2006) Drug costs associated with non-adherence to cholesterol management guidelines for primary prevention of cardiovascular disease in an elderly population: the Rotterdam study. Drugs Aging 23 (9):: 733-41.
68. Taylor F, Huffman MD, Macedo AF, Moore THM, Burke M, et al. (2013) Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews, Issue 1. Art. No.: CD004816. DOI: 10.1002/14651858.CD004816.pub5.